Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.40 |
| ▸ | PDE5A | O76074 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944099 | 0.91 | PDE4B (0.41) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL1944016 | 0.91 | PDE4B (0.37) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL1943239 | 0.89 | PDE4B (0.37) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL1945316 | 0.89 | PDE4B (0.34) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL1944435 | 0.89 | PDE4B (0.38) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL1944856 | 0.86 | PDE4B (0.34) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL1943076 | 0.85 | PDE4B (0.41) | PDE4BPDE5APOLB | |
| SCHEMBL1944026 | 0.85 | PDE4B (0.35) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL1942906 | 0.85 | PDE4B (0.34) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL1944813 | 0.85 | PDE4B (0.34) | PDE4BPDE5AMEN1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-06-02 | — | — | US | claimed |
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130403-A1 | PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3B, PDE4B | PDE4B 3/4885PDE5A 6/4885POLB 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.